文献速递神经免疫

利妥昔单抗与其他初始治疗选择对多发性硬化的比较有效性

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项回顾性队列研究基于瑞典两个县的新诊断复发缓解型多发性硬化患者,比较利妥昔单抗与可注射疾病修饰治疗、富马酸二甲酯、芬戈莫德或那他珠单抗的有效性和停药率。结果显示利妥昔单抗的停药率最低,临床复发和/或神经影像学疾病活动度显著低于可注射疾病修饰治疗和富马酸二甲酯,与那他珠单抗和芬戈莫德比较有更低趋势但未达显著。

要点

  • 利妥昔单抗年停药率为0.03,低于可注射疾病修饰治疗(0.53)、富马酸二甲酯(0.32)、芬戈莫德(0.38)和那他珠单抗(0.29)。
  • 利妥昔单抗的临床复发和/或神经影像学疾病活动度显著低于可注射疾病修饰治疗和富马酸二甲酯。
  • 与那他珠单抗和芬戈莫德比较,利妥昔单抗的复发率有更低趋势,但为临界显著性。

核心结论

  • 利妥昔单抗在停药方面优于所有其他疾病修饰治疗,临床疗效优于可注射疾病修饰治疗和富马酸二甲酯,与那他珠单抗和芬戈莫德比较为临界显著性。
  • 利妥昔单抗作为主要初始治疗选择的县在多数测量变量上显示更好的结局。
  • 作者认为,在新诊断复发缓解型多发性硬化患者中,利妥昔单抗的表现优于其他常用疾病修饰治疗。

研究设计与样本

  • 回顾性队列研究,使用前瞻性收集的数据,纳入瑞典斯德哥尔摩和西博滕两个县社区样本中2012年1月1日至2015年10月31日诊断的复发缓解型多发性硬化患者。
  • 共纳入494例患者,中位年龄34.4岁(四分位距27.4-43.4),男性158例(32.0%)。

主要发现

  • 215例(43.5%)接受可注射疾病修饰治疗,86例(17.4%)接受富马酸二甲酯,17例(3.4%)接受芬戈莫德,50例(10.1%)接受那他珠单抗,120例(24.3%)接受利妥昔单抗,6例(1.2%)接受其他疾病修饰治疗。
  • 利妥昔单抗、可注射疾病修饰治疗、富马酸二甲酯、芬戈莫德和那他珠单抗的年停药率分别为0.03、0.53、0.32、0.38和0.29。
  • 可注射疾病修饰治疗、富马酸二甲酯和芬戈莫德停药的主要原因是持续疾病活动;那他珠单抗停药的主要原因是John Cunningham病毒血清学阳性。
  • 利妥昔单抗的临床复发和/或神经影像学疾病活动度显著低于可注射疾病修饰治疗和富马酸二甲酯,与那他珠单抗和芬戈莫德比较复发率有更低趋势。
  • 西博滕县初始治疗选择的年停药率显著低于斯德哥尔摩县(分别为0.09和0.37)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Comparative real-world effectiveness studies of initial disease-modifying treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include rituximab are lacking. OBJECTIVE: To assess the effectiveness and drug discontinuation rates of rituximab among patients with newly diagnosed RRMS compared with injectable DMTs, dimethyl fumarate, fingolimod, or natalizumab. DESIGN, SETTING, AND PATIENTS: This retrospective cohort study used prospectively collected data to examine specialized care of 2 Swedish county-based community samples of patients with RRMS. Patients with RRMS who received diagnoses from January 1, 2012, to October 31, 2015, who resided in Stockholm or Västerbotten Counties were identified from a Swedish multiple sclerosis registry. MAIN OUTCOMES AND MEASURES: All reasons for drug discontinuation of initial treatment choice (main outcome) and specific reasons for switching (secondary outcomes) were analyzed with multivariable Cox regression, including propensity scores. RESULTS: Among 494 patients (median [interquartile range] age, 34.4 [27.4-43.4] years; 158 men [32.0%]), 215 received an injectable DMT (43.5%); 86 (17.4%), dimethyl fumarate; 17 (3.4%), fingolimod; 50 (10.1%), natalizumab; 120 (24.3%), rituximab; and 6 (1.2%), other DMT. Regional preferences were pronounced, with 42 of 52 (81%) and 78 of 442 (18%) receiving rituximab in Västerbotten and Stockholm, respectively. The annual discontinuation rate for rituximab, injectable DMTs, dimethyl fumarate, fingolimod, and natalizumab were 0.03, 0.53, 0.32, 0.38, and 0.29, respectively. Continued disease activity was the main reason for discontinuation of injectable DMTs, dimethyl fumarate, and fingolimod; positive John Cunningham virus serology results were the main reason for discontinuation of natalizumab. Rate of clinical relapses and/or neuroradiologic disease activity were significantly lower for rituximab compared with injectable DMTs and dimethyl fumarate, with a tendency for lower relapse rates also compared with natalizumab and fingolimod. The annual discontinuation rate of initial treatment choice was significantly lower in Västerbotten compared with Stockholm (0.09 and 0.37, respectively). CONCLUSIONS AND RELEVANCE: Rituximab was superior to all other DMT in terms of drug discontinuation and displayed better clinical efficacy compared with injectable DMTs and dimethyl fumarate with borderline significance compared with natalizumab and fingolimod. The county where rituximab constituted the main initial treatment choice displayed better outcomes in most measured variables. Collectively, our findings suggest that rituximab performs better than other commonly used DMTs in patients with newly diagnosed RRMS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Granqvist M, Boremalm M, Poorghobad A, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol. 2018. PMID: 29309484. doi:10.1001/jamaneurol.2017.4011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。